Molecular markers in urologic oncology: prostate cancer

The increased clinical availability of a wide variety of molecular tests will potentially reshape the care of both men at risk for prostate cancer and men already diagnosed. It is imperative that clinicians be familiar with indications and clinical relevance of these tests.

The continued clinical validation in new and expanded clinical cohorts and reports of clinical experience with various molecular markers is a rapidly evolving body of literature. Results of large patient series demonstrate that these markers increase the precision of available information used in clinical management decision-making and joint physician-patient discussions regarding treatment options.

These tests may make more accurate management decisions possible for those whom have been 'over-diagnosed' with biologically indolent disease which represents an exceptionally small mortality risk. They also may aid in more accurate diagnosis of significant cancer, as well as more precise application of adjuvant therapy.

Current opinion in urology. 2016 Jan 28 [Epub ahead of print]

Chad A Reichard, Andrew J Stephenson, Eric A Klein

Cleveland Clinic Glickman Urological and Kidney Institute, Cleveland, Ohio, USA.

PubMed

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe